As we move forward in clinical trials for autologous and allogeneic stem cell therapies, recognition of what we don't know and what we do is both critical and constantly changing. The integration of this expanding stem cell knowledge with the parallel expansion of our knowledge of the biochemestry and molecular biology of the human body will hopefully produce continually improving therapies. However, the acquisition of knowledge and understanding is not linear. Research in therapies can get ahead of our understanding of disease process and have. This video is a reality check on what we know of neurodegenerative disease and potential therapy as of October 2011. It is well worth watching.
Taking place at the World Stem Cell Summit, this talk is about 37 minutes long. With an emphasis on Alzheimer's disease, Dr. Goldstein does a truly excellent job of pointing out the difficulty of understanding
Dr. Goldstein is Professor of Cellular and Molecular Medicine at the University of California, San Diego, School of Medicine. He is also an Investigator with the Howard Hughes Medical Institute.
He was Assistant, Associate and Full Professor at Harvard University in the Department of Cellular and Developmental Biology from 1984-1993 and moved to UCSD and HHMI in 1993. His awards include a Senior Scholar Award from the Ellison Medical Foundation, an American Cancer Society Faculty Research Award, and the Loeb Chair in Natural Sciences when he was at Harvard University. His research is focused on understanding the molecular mechanisms of intracellular movement in neurons and the role of transport dysfunction in neurodegenerative diseases. His lab provided the first molecular descriptions of kinesin structure and organization, and has recently discovered important links between transport processes and diseases such as Alzheimers Disease and Huntingtons Disease.
Comments